The website domain reflects its role for my own purpose only. Viewing of the webpages by others is not approved.
Main Index Site Developments
Patient Information Conditions of Use



---
Myocardial Infarction
Optimising Drug Therapy

Warfarin for Secondary Prevention

A number of studies have examined the use of warfarin for secondary prevention. In some studies “low-dose warfarin” plus low dose aspirin was compared with aspirin alone. Other studies compared “theurapeutic” dose warfarin plus aspirin with aspirin alone. Warfarin has also been compared directly with low dose aspirin.

The conclusions that have been reached regarding use of warfarin for secondary prevention are:

  • Warfarin is an alternative for patients that can not take low dose aspirin
  • Warfarin alone may be superior to low dose aspirin alone
  • Low dose warfarin plus low dose aspirin it not better than low dose aspirin alone
  • Theurapeutic dose warfarin plus low dose aspirin may be superior to low dose aspirin alone or to warfarin alone
  • There is no comparision to date of aspirin with clopidogrel vs aspirin with theurapeutic dose warfarin.

The use of warfarin for secondary prevention has not been widely accepted, presumably because of the need for regular monitoring and the increased risk of bleeding. However, we should consider the use of warfarin plus low dose aspirin in some high risk patients who continue to have events despite use of all appropriate secondary prevention measures.

Hitesh Patel, Cardiologist
5th June, 2004

References:
CLINICIAN UPDATE. Oral Anticoagulation for Acute Coronary Syndromes. Circulation 2002:1270-1274

Users should read this document on "copyright" and "conditions of use".